A Phase 2, Randomized, Open-Label Active-Comparator (Epoetin Alfa) Dose-Ranging Safety and Exploratory Efficacy Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis (HD)

Trial Profile

A Phase 2, Randomized, Open-Label Active-Comparator (Epoetin Alfa) Dose-Ranging Safety and Exploratory Efficacy Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis (HD)

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Roxadustat (Primary) ; Epoetin alfa
  • Indications Anaemia
  • Focus Therapeutic Use
  • Sponsors FibroGen
  • Most Recent Events

    • 30 Mar 2017 Results from this trial were published in Nephrology Dialysis Transplantation, according to a FibroGen media release.
    • 30 Mar 2017 Results published in a FibroGen media release.
    • 30 Mar 2017 Primary endpoint (Haemoglobin level (Number of patients whose haemoglobin levels are maintained at no lower than 0.5 g/dL below their mean baseline value during weeks 6 and 7.)) has been met, according to a FibroGen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top